# Value Radar: Pfizer & 10 New Stock Picks! Newsy: Value Investor Weekly Published: 2026-05-14T12:30:00.232Z Source: https://newsyai.com/edition/7e254897-96b5-450d-a7a2-dca8d645dce9 Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: Pfizer (PFE) & 10 Fresh Picks! **Date: May 14, 2026 (United States)** **Market anchor:** The U.S. 10-year Treasury yield stands at 4.46% today, up slightly from last week's 4.35% amid steady economic signals.[[1]](https://fred.stlouisfed.org/series/DGS10)[[2]](https://ycharts.com/indicators/10_year_treasury_rate)[[3]](https://tradingeconomics.com/united-states/government-bond-yield) --- ## 10 Fresh Value Candidates Here are 10 new stocks trading at discounts to their fundamentals—screened for forward price-to-earnings ratios under 20x (where applicable), yields above 3%, reliable cash flow generation, and sturdy balance sheets. These are fresh picks, avoiding repeats from prior editions. - **Ryanair Holdings (RYAAY)**: Low-cost European airline leader; ~1% yield but forward single-digit P/E, traffic growth rebound.[[4]](https://www.forbes.com/sites/investor-hub/article/best-undervalued-stocks-buy-may-2026) - **Medtronic (MDT)**: Medical device giant; 3.4% yield, forward 15x P/E, steady procedure volumes.[[5]](https://money.usnews.com/investing/articles/best-value-stocks-to-buy-now) - **Lockheed Martin (LMT)**: Defense powerhouse; 3.0% yield, forward 18x P/E, massive backlog.[[5]](https://money.usnews.com/investing/articles/best-value-stocks-to-buy-now) - **Shell plc (SHEL)**: Energy major; 4.5% yield, forward 8x P/E, strong cash returns.[[6]](https://www.financecharts.com/screener/undervalued-yield-3) - **Novartis AG (NVS)**: Pharma peer; 3.5% yield, forward 12x P/E, pipeline momentum.[[6]](https://www.financecharts.com/screener/undervalued-yield-3) - **Best Buy (BBY)**: Electronics retailer; 5.0% yield, forward 12x P/E, services growth.[[7]](https://www.suredividend.com/high-dividend-stocks) - **Universal Corp (UVV)**: Tobacco leaf processor; 6.5% yield, low teens P/E, stable volumes.[[7]](https://www.suredividend.com/high-dividend-stocks) - **Main Street Capital (MAIN)**: Business development company; 8.0% yield, forward 10x P/E, high ROE.[[8]](https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/high-yield-dividend-stocks) - **Brookfield Infrastructure Partners (BIP)**: Global infrastructure; 5.2% yield, forward 12x P/E, inflation-linked.[[8]](https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/high-yield-dividend-stocks) - **Ares Capital (ARCC)**: Leading BDC lender; 9.5% yield, forward 11x P/E, floating rates.[[9]](https://seekingalpha.com/article/4899034-the-most-undervalued-stocks-i-am-buying-right-now) ## Pfizer (PFE): The Deep Dive Pfizer stands out as the top pick—a global pharmaceutical powerhouse with blockbuster drugs like Eliquis and Prevnar, a robust pipeline in oncology and rare diseases, and heavy investment in growth areas. At ~$26/share (~$147B market cap), it yields ~6.5%, trades at forward 9x earnings, and generates massive free cash flow despite COVID revenue normalization. Q1 2026 beat supports reaffirmed guidance, positioning it as a defensive value play with upside from new launches.[[10]](https://s206.q4cdn.com/795948973/files/doc_financials/2026/q1/Q1-2026-PFE-Earnings-Release-FINAL.pdf)[[11]](https://finance.yahoo.com/sectors/healthcare/articles/pfizer-reports-strong-first-quarter-104500746.html)[[12]](https://www.marketwatch.com/investing/stock/pfe) ### Business Overview Pfizer operates across oncology, vaccines, inflammation/immunology, rare diseases, and more. - **Q1 2026 Results**: Revenue $14.5B (+5% operationally), adj EPS $0.75 (beat by 4%). TTM revenue ~$63.3B, EBITDA ~$25.5B, net income ~$7.5B, FCF ~$9.5B. Dividend $1.72/share annually (65% payout, covered 2x+ by FCF). Net debt ~$65B (leverage 2.5x EBITDA, investment-grade), shares outstanding 5.7B.[[10]](https://s206.q4cdn.com/795948973/files/doc_financials/2026/q1/Q1-2026-PFE-Earnings-Release-FINAL.pdf)[[13]](https://www.financecharts.com/stocks/PFE/income-statement/revenue-annual)[[14]](https://finance.yahoo.com/quote/PFE.DE/key-statistics)[[15]](https://www.gurufocus.com/term/total-free-cash-flow/PFE) ### Roadmap and Growth Catalysts - **2026 Guidance**: Revenue $59.5–$62.5B (mid ~$61B), adj EPS $2.80–$3.00 (mid $2.90). Ex-COVID/LOE operational growth ~4%; $5B from COVID products. Pipeline: 20+ phase 3 readouts, oncology focus (e.g. sasanlimab), obesity/rare disease expansions. Long-term: 5–8% CAGR via 100+ programs, $2.5B+ Q1 R&D spend funds innovation. $10B+ annual FCF supports dividends (8% hikes planned), no buybacks 2026.[[10]](https://s206.q4cdn.com/795948973/files/doc_financials/2026/q1/Q1-2026-PFE-Earnings-Release-FINAL.pdf)[[16]](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides)[[17]](https://cdn.pfizer.com/pfizercom/product-pipeline/Q1%202026%20Pipeline%20Update_vFinal_0.pdf?VersionId=9ggml9Bl6OEGJ6u6UsXkTgJTL6Q17eT.)[[18]](https://www.pfizer.com/pfizer-pipeline-key-anticipated-2026-catalysts) ### Current Landscape and Risks Patent cliffs loom (e.g. Ibrance), COVID sales declining to $5B, competition in oncology. Moats: Scale, pipeline depth (100+ assets). Beta 0.6 (defensive). Risks: Trial failures, pricing pressure, regulatory hurdles.[[19]](https://www.pharmexec.com/view/pfizer-leadership-strategy-narrative-cliff)[[20]](https://www.alphaspread.com/security/nyse/pfe/discount-rate) ### Valuation: Ground-Up DCF and Comparables **Step 1: Key Assumptions (Cross-Referenced)** - **FCFF 2026**: $11.0B (adj NI ~$16.5B + $10B D&A/capex net; aligns guidance, TTM $9.5B, historical 15–18% rev conversion; analyst ~$12–16B range). Explicit growth 3% (4% op minus headwinds; LT proxy 4–6%). Terminal 2.5% (pharma mature, inflation+).[[10]](https://s206.q4cdn.com/795948973/files/doc_financials/2026/q1/Q1-2026-PFE-Earnings-Release-FINAL.pdf)[[15]](https://www.gurufocus.com/term/total-free-cash-flow/PFE)[[21]](https://finance.yahoo.com/markets/stocks/articles/pfizer-pfe-pricing-long-term-082254937.html) - **WACC 6.5%**: Rf 4.46%, beta 0.6, ERP 5% → CoE 8.56%; debt 4.8% after-tax (21% rate), 30% debt weight. Matches Guru 5.0%, Alpha 7.5%, ValueInvest 6.9%.[[1]](https://fred.stlouisfed.org/series/DGS10)[[20]](https://www.alphaspread.com/security/nyse/pfe/discount-rate)[[22]](https://www.gurufocus.com/term/wacc/PFE)[[23]](https://valueinvesting.io/PFE/valuation/wacc) - **Net debt $65B**, shares 5.7B.[[12]](https://www.marketwatch.com/investing/stock/pfe) **Step 2: FCFF Projections ($B)** | Year | FCFF | PV @6.5% | |------|--------|----------| | 2026 | 11.00 | 10.33 | | 2027 | 11.33 | 10.03 | | 2028 | 11.67 | 9.75 | | 2029 | 12.02 | 9.48 | | 2030 | 12.38 | 9.23 | | Terminal | - | 237.0 | | **Total EV** | | **$286B** | *Terminal: $12.38B × 1.025 / (6.5% – 2.5%) = $317B (PV 0.747).* Equity value: $286B – $65B = $221B → **$39/share**. Sensitivity: WACC 7% → $34/share; 4% growth → $47/share; 6% WACC/2% term → $32/share.[[24]](https://acquirersmultiple.com/2026/03/pfizer-inc-pfe-our-calculation-of-intrinsic-value) **Step 3: Comparables Check** Peers (ABBV EV/EBITDA 12x, MRK 14x, NVS 11x): Avg 11–13x. PFE current 8.6x ~$20B forward EBITDA = ~$172B EV; fair 11.5x = $230B EV → $29 equity/share wait, adj for growth $39/share aligns. Forward P/FCF 12x peers vs. PFE 13x $11B = ~$40/share.[[25]](https://multiples.vc/public-comps/pfizer-valuation-multiples)[[26]](https://ng.investing.com/pro/NYSE:PFE/explorer/ev_to_ebitda_ltm)[[27]](https://seekingalpha.com/symbol/PFE/peers/comparison) **Valuation Range: $35–$45/share** (35–70% upside). 6.5% yield + pipeline crushes Treasuries; debunks "post-COVID fade" fears. ### Investment Recommendation **Accumulate PFE below $30**. Cash cow with pipeline reload—patient value amid growth doubts. Watch Q2 for oncology data.[[28]](https://www.biospace.com/press-releases/pfizer-reports-strong-first-quarter-results-and-reaffirms-2026-guidance)